Tryp Therapeuatics (TRYPF) Coverage Report

keep additional key personnel, they may be unable to successfully develop or commercialize our drug candidates. Operational risks. The company may engage in strategic transactions that could impact liquidity, increase expenses, and present significant distractions to management. As COVID-19 continues to be present and spread around the globe, the company may experience additional disruptions that could severely impact business and clinical trials. The directors and officers may have conflicts of interest with the Company. The company has limited operating history may make it difficult for an investor to evaluate the success of the company’s business to date and to assess the company’s future viability. The company’s executive officers, directors and certain significant shareholders will continue to own a substantial number of Common Shares and, as a result, may be able to exercise control over the company, including the outcome of shareholder votes. Michael Higgins 212.409.2074 Tryp Therapeutics, Inc. (TRYPF) Page 39